{"filings":[{"id":2854156,"accession_number":"0002019410-26-000061","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2026-09-14T20:38:06+00:00","items":["7.01"],"status":"ready","headline":"Caris Life Sciences discloses investor presentation for Morgan Stanley healthcare conference","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Announces use of investor presentation at Morgan Stanley 24th Annual Global Healthcare Conference on Sept 14, 2026.","Presentation to be posted on IR website at investor.carislifesciences.com.","Filing discloses no new financial or operational information beyond presentation availability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2079086,"accession_number":"0002019410-26-000053","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2026-08-05T20:12:27+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caris Life Sciences Q2 revenue up 45% to $263.7M; raises FY 2026 guidance to $1.03-1.04B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $263.7M (+45% YoY); net loss narrowed to $0.6M from $71.8M loss; positive Adj. EBITDA $55.7M.","Clinical cases ~59,200 (+18% YoY); gross margin improved 500 bps to 68%.","Raised 2026 revenue guidance to $1.03-1.04B (27-28% growth); reaffirmed ~20% clinical therapy selection volume growth.","Launched Caris Detect multi-cancer early detection blood test and Caris ChromoSeq for myeloid malignancies.","Share repurchase program of up to $100M authorized; $82.1M remains available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":890396,"accession_number":"0002019410-26-000046","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2026-06-05T21:03:34+00:00","items":["5.07"],"status":"ready","headline":"Caris Life Sciences shareholders elect ten directors, ratify Deloitte as auditor for FY2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting held June 4, 2026; 273.7M shares represented (96.8% of 282.7M outstanding).","All ten director nominees elected with votes ranging from 200.4M to 228.7M in favor.","Deloitte & Touche LLP ratified as independent auditor: 273.5M for, 60.9K against, 136.3K abstentions.","Broker non-votes of 11.1M recorded on director election but not on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97234,"accession_number":"0002019410-26-000040","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caris Life Sciences Q1 revenue up 79% to $216.2M, net loss narrows to $0.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $216.2M (+79% YoY); gross margin 65% vs 47% a year ago.","Net loss $0.5M vs $102.6M loss in Q1 2025; positive Adj. EBITDA $26.2M.","Completed ~52,800 clinical cases (+15% YoY); reaffirms FY2026 revenue guidance $1.0-$1.02B.","Free cash flow positive $22.5M, inclusive of $30.5M annual bonus payments.","Launched MolDX-approved Caris ChromoSeq; refinanced $400M credit facility with Blue Owl/Blackstone."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":216174000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97233,"accession_number":"0002019410-26-000019","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","1.02","2.03"],"status":"ready","headline":"Caris Life Sciences enters $400M term loan and $300M delayed draw facility with Blue Owl and Blackstone","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $400M initial term loan to repay existing credit agreement from January 2023.","Additional $300M delayed draw facility for acquisitions available through August 2027.","Uncommitted incremental capacity up to $500M; loans priced at SOFR + 5.00%.","Credit agreement matures April 2031; secured by substantially all assets.","Must maintain minimum $50M qualified cash tested quarterly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111833,"accession_number":"0002019410-26-000011","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Caris Q4 net income $82M; FY25 rev $812M (+97%); guides FY26 rev $1.0-1.02B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $292.9M (+125% YoY); net income $82.0M vs loss of $36.9M prior year.","Full year 2025 revenue $812.0M (+97% YoY); net loss narrowed to $68.1M from $281.9M; Adj. EBITDA $137.7M.","Gross margin improved to 75% in Q4 (from 54%) and 66% for FY (from 43%).","FY26 revenue guidance $1.0-1.02B (23-26% growth); molecular profiling rev growth ~21-22%.","Interim readout of Achieve 1 study for Caris Detect MCED test completed; launch expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":812033000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111832,"accession_number":"0002019410-26-000005","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Caris Life Sciences reports preliminary Q4 2025 revenue of ~$281M, up 116% YoY; FY revenue ~$800M, up 94%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue ~$281M (+116% YoY); Molecular Profiling services ~$270M including ~$81M prior-period true-ups.","Full-year 2025 revenue ~$800M (+94% YoY); Pharma R&D services ~$45M.","Q4 clinical therapy selection cases ~52,700 (+20%); full-year ~199,300 (+22%).","Cash, equivalents and marketable securities ~$802M as of Dec 31, 2025, up ~$43M from Sep 30, 2025.","Company presenting at 44th J.P. Morgan Healthcare Conference today; complete earnings call expected in late Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":812033000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128457,"accession_number":"0002019410-25-000026","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caris Life Sciences Q3 revenue $216.8M, up 113%, raises FY2025 guidance to $720-730M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $24.3M vs. loss of $67.7M YoY; diluted EPS $0.08 vs. ($2.59).","Gross margin expanded to 68.0% from 43.7% YoY; clinical cases up 18.2% to 50,763.","Positive Adjusted EBITDA of $51.2M and free cash flow of $55.3M.","Full-year 2025 revenue guidance raised to $720-730M, representing 75-77% YoY growth.","Molecular profiling services revenue grew 121.3% YoY to $207.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":519147000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128456,"accession_number":"0002019410-25-000020","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Caris Life Sciences adopts 3% ownership threshold for derivative proceedings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to bylaws on October 30, 2025 requiring 3% beneficial ownership to institute or maintain a derivative proceeding.","Threshold applies to any shareholder or group of shareholders acting together under the Texas Business Organizations Code.","Changes are effective immediately; full text of amended bylaws filed as Exhibit 3.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145253,"accession_number":"0002019410-25-000011","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Caris Life Sciences Q2 2025 revenue $181.4M (+81% YoY); Adj. EBITDA positive $16.7M; FY rev guidance $675-685M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $181.4M, up 81.3% YoY; gross margin 62.7% vs 37.5% a year ago.","Net loss $71.8M includes $37.1M one-time IPO conversion expense; positive Adj. EBITDA $16.7M and positive free cash flow $5.9M.","Clinical therapy selection volume 50,032 cases (+22% YoY); MI Profile volume +17.7%, Caris Assure volume +56.3%.","FY2025 revenue guidance $675-685M (64-66% growth); clinical volume growth expected 19-21%.","Recent IPO raised $519.5M net; cash and securities $724.9M at June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":302314000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163674,"accession_number":"0001104659-25-061148","cik":2019410,"company_name":"Caris Life Sciences, Inc.","ticker":"CAI","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Caris Life Sciences completes IPO of 23.5M shares at $21.00, raising $494.1M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 23,529,412 shares of common stock at $21.00 per share closed June 20, 2025.","Gross proceeds of $494.1 million before underwriting discounts and estimated offering expenses.","Amended and restated certificate of formation and bylaws became effective upon IPO closing.","Shares trade on Nasdaq under ticker CAI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4627483004.717164,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}